Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | MIF | P14174 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30876859 | 1.00 | TAAR1 (0.67) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL7988615 | 0.98 | TAAR1 (0.65) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| Methylamine SCHEMBL11065026 | 0.96 | TAAR1 (0.68) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| Ethylamine SCHEMBL28258055 | 0.94 | TAAR1 (0.71) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL27360531 | 0.90 | TAAR1 (0.56) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL18015796 | 0.89 | TAAR1 (0.54) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL256694 | 0.89 | TAAR1 (0.62) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL7929109 | 0.87 | TAAR1 (0.61) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL2094737 | 0.85 | TAAR1 (0.59) | TAAR1HTR2AHTR2BSIGMAR1LMNA | |
| SCHEMBL28260251 | 0.85 | TAAR1 (0.59) | TAAR1HTR2AHTR2BSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090941-A1 | CALCIUM SENSING RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-4276089-A2 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | Universite De Moncton (CA) | 2023-11-15 | — | — | EP | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| EP-3878841-B1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | TARAPEUTICS SCIENCE INC (CN) | 2023-10-18 | — | — | EP | disclosed |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023177877-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0850926-B1 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | disclosed |
| US-5985920-A | COMPOUNDS FOR TREATMENT OF VISION DEFECTS SUCH AS GLAUCOMA | ASAHI GLASS COMPANY LTD. (JP) | 1999-11-16 | — | — | US | disclosed |
| US-5886035-A | PREVENTIVE AND THERAPEUTICAL MEDICINE FOR EYE DISEASE | ASAHI GLASS COMPANY LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0850926-A2 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS COMPANY LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | disclosed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | disclosed |
| EP-0597088-A1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993014070-A2 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | TAAR1 285/4885HTR2A 1540/4885HTR2B 809/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | TAAR1 3661/4885HTR2A 4330/4885HTR2B 4703/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | TAAR1 4498/4885HTR2A 3850/4885HTR2B 3492/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | TAAR1 2803/4885HTR2A 4616/4885HTR2B 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.